Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.

Abstract

Insulin glargine 300 U/mL (Toujeo(®)) is a long-acting basal insulin analogue approved for the treatment of diabetes mellitus. Insulin glargine 300 U/mL has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus(®)), with a duration of glucose-lowering activity exceeding 24 h. In several 6-month phase III trials, insulin glargine 300 U/mL achieved comparable glycaemic control to that seen with insulin glargine 100 U/mL in patients with type 1 or type 2 diabetes, albeit with consistently higher daily basal insulin requirements. These improvements in glycaemic control were maintained during longer-term (12 months) treatment. Insulin glargine 300 U/mL was generally associated with a lower risk of nocturnal hypoglycaemia than insulin glargine 100 U/mL in insulin-experienced patients with type 2 diabetes, while the risk of nocturnal hypoglycaemia did not significantly differ between treatment groups in insulin-naïve patients with type 2 diabetes or in patients with type 1 diabetes. To conclude, once-daily subcutaneous insulin glargine 300 U/mL is an effective and generally well tolerated basal insulin therapy option for patients with type 1 or type 2 diabetes.

• Authors: Hannah A Blair, Gillian M Keating
• Journal: Drugs (Drugs) Vol. 76 Issue 3 Pg. 363-74 (Mar 2016) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 26821280 (Publication Type: Journal Article, Review)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Insulin Glargine

Topics

• Blood Glucose (analysis)
• Clinical Trials, Phase III as Topic
• Diabetes Mellitus (blood, drug therapy)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Humans
• Hypoglycemic Agents (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Infant, Newborn, Diseases (blood, drug therapy)
• Injections, Subcutaneous
• Insulin Glargine (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Time Factors
• Treatment Outcome